Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents.
Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis / F. Atzeni, L. Costa, F. Caso, R. Scarpa, P. Sarzi-Puttini. - In: THE JOURNAL OF RHEUMATOLOGY. SUPPLEMENT. - ISSN 0380-0903. - 93(2015 Nov), pp. 79-81.
|Titolo:||Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis|
|Parole Chiave:||Psoriatic arthritis; tumor necrosis factor; apremilast; ustekinumab; interleukin-17 inhibitors; rituximab|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||nov-2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3899/jrheum.150643|
|Appare nelle tipologie:||01 - Articolo su periodico|